Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Danvilostomig in Solid tumor: NCT05965856 Clinical Landscape Report 2026
16 October 2026
NCT05965856 clinical landscape for Solid tumor: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Sulfur Hexafluoride in Triple Negative Breast Cancer: NCT05957042 Clinical Landscape Report 2026
16 October 2026
NCT05957042 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Axitinib in Thrombosis: NCT05969496 Clinical Landscape Report 2026
16 October 2026
NCT05969496 clinical landscape for Thrombosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
SP-3164 in Mantle-Cell Lymphoma: NCT05979857 Clinical Landscape Report 2026
16 October 2026
NCT05979857 clinical landscape for Mantle-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Izalontamab Brengitecan in Endometrial Carcinoma: NCT05983432 Clinical Landscape Report 2026
16 October 2026
NCT05983432 clinical landscape for Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
![[177Lu]Lu-FF58 in Glioblastoma Multiforme: NCT05977322 Clinical Landscape Report 2026](https://synapse-static.patsnap.com/strapi-static/Blog_cover_B_86_48077a7b89.jpg)
9 min read
[177Lu]Lu-FF58 in Glioblastoma Multiforme: NCT05977322 Clinical Landscape Report 2026
16 October 2026
NCT05977322 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pembrolizumab in Glioblastoma Multiforme: NCT05973903 Clinical Landscape Report 2026
16 October 2026
NCT05973903 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pitavastatin Calcium in Glioblastoma Multiforme: NCT05977738 Clinical Landscape Report 2026
16 October 2026
NCT05977738 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pembrolizumab in Triple Negative Breast Cancer: NCT05973864 Clinical Landscape Report 2026
16 October 2026
NCT05973864 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Etoposide in B-Cell Lymphoma: NCT05991388 Clinical Landscape Report 2026
16 October 2026
NCT05991388 clinical landscape for B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cyclophosphamide in Diffuse Large B-Cell Lymphoma: NCT05990985 Clinical Landscape Report 2026
16 October 2026
NCT05990985 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Anti-CD19 and anti-CD20 CAR-T cell therapy(The Medical College of Wisconsin, Inc.) in Mantle-Cell Lymphoma: NCT05990465 Clinical Landscape Report 2026
16 October 2026
NCT05990465 clinical landscape for Mantle-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.